Table 2.
Meta-analysis (MA) | Exposure assessment | Outcome assessment | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Data source presented in MA | Cohort studies (n) | Case-control studies (n) | Data source presented in MA | Cohort studies (n) | Case-control studies (n) | |||||||||
1ry | 2ry | NR | 1ry | 2ry | NR | 1ry | 2ry | NR | 1ry | 2ry | NR | |||
Weiss J [20] Harms outcomes |
No | . | . | . | . | . | . | No | . | . | . | . | . | . |
Bally M [21] | Yes | 0 | 3b | 0 | 0 | 1 | 0 | Yes | 0 | 3b | 0 | 0 | 1 | 0 |
Sordo L [22] | Noa | . | . | . | . | . | . | Noa | . | . | . | . | . | . |
Tariq R [23] | Noac | . | . | . | . | . | . | Noa | . | . | . | . | . | . |
Maruthur NM [24] | Yesd | 0 | 3 | 0 | . | . | . | Yesd | 0 | 3 | 0 | . | . | . |
Paul S [25] | Noa | . | . | . | . | . | . | Noa | . | . | . | . | . | . |
Li L [26] Heart failure |
Yes | 0 | 1 | 2 | 0 | 0 | 1 | Yes | 1 | 0 | 2 | 0 | 0 | 1 |
Li L [26] Hospital admissions for heart failure |
Yes | 0 | 0 | 6 | 0 | 0 | 2 | Yes | 3 | 0 | 3 | 0 | 0 | 2 |
Molnar AO [27] | Noa | . | . | . | . | . | . | Noa | . | . | . | . | . | . |
Ziff OJ [28] | Noa | . | . | . | . | . | . | Noa | . | . | . | . | . | . |
CGESOC [29] | No | . | . | . | . | . | . | No | . | . | . | . | . | . |
Bellemain-Appaix A [30] | Noa | . | . | . | . | . | . | Noa | . | . | . | . | . | . |
Grigoriadis S [31] | Yes | 2 | 3 | 0 | 1 | 1 | 0 | Yes | 4 | 1 | 0 | 2 | 0 | 0 |
Li L [32] | Yes | 0 | 1 | 2 | 0 | 1 | 1 | Yes | 1 | 2 | 0 | 0 | 0 | 2 |
Kalil AC [33] | No | . | . | . | . | . | . | No | . | . | . | . | . | . |
Stegeman BH [34] | Yes | 0 | 9 | 0 | 8 | 8 | 1 | Yes | 4 | 5 | 0 | 5 | 12 | 0 |
Maneiro JR [35] | Noa | . | . | . | . | . | . | Noa | . | . | . | . | . | . |
Hartling L [36] | No | . | . | . | . | . | . | No | . | . | . | . | . | . |
Hsu J [37] | Noa | . | . | . | . | . | . | Noa | . | . | . | . | . | . |
Caldeira D [38] | Yes | 2 | 2 | 7 | 0 | 7 | 1 | Yes | 0 | 1 | 10 | 3 | 1 | 4 |
MacArthur GJ [39] | Noa | . | . | . | . | . | . | Noa | . | . | . | . | . | . |
Mantha S [40] | No | . | . | . | . | . | . | No | . | . | . | . | . | . |
Silvain J [41] | Yes | 0 | 7 | 0 | . | . | . | Yes | 0 | 7 | 0 | . | . | . |
McKnight RF [42] | No | . | . | . | . | . | . | No | . | . | . | . | . | . |
Abbreviations: 1ry number of individual studies in each MA based on primary data sources, 2ry number of individual studies in each MA based on secondary data sources, NR number of individual studies in each MA with not reported data source
aAlthough the meta-analysis shows the results of methodological quality assessment based on a standardized scale, it does not indicate the type of data source used for each individual observational study included in the meta-analysis
bCohort with nested case-control analysis
cThe meta-analysis reports that most of the included observational studies assessed medication exposure through a review of medical records
dThe meta-analysis reports only data from high-quality observational studies